Published in Blood Weekly, July 13th, 2006
According to recent research from Japan, "CLL is a low-grade lymphoid malignancy incurable with conventional modalities of chemotherapy. Strong and constitutive nuclear factor kappa B (NF-kappa B) activation is a characteristic of CLL cells."
"We examined the effects of a new NF-kappa B inhibitor, DHMEQ, on CLL cells. Dehydroxymethylepoxyquinomicin completely abrogated constitutive NF-kappa B activity and induced apoptosis of CLL cells. Apoptosis induced by DHMEQ was accompanied by downregulation of NF-kappa B-dependent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly